DailyIQ
DailyIQ
Last updated6 days ago

KVUE·Kenvue Inc.

$19.27
-0.29 (-1.48%)
Market Closed (Overnight)$19.60+0.33 (+1.71%)
High
$0.00
Open
$0.00
Market Cap
37.09B
52W High
$20.13
Low
$0.00
P. Close
$19.27
P/E
22.37
52W Low
$15.94
Fwd P/E
15.58
DailyIQ Est.
$19.51
Inst. Own.
79.7%
Short Interest
2.94%
Days to Cover
2.7
Div. Yield
4.28%
Next Ex-Div
~Jan 29
NewEarnings release, scored · filed Oct 30, 2026tone -8.3 vs prior release · 125 lines scoredSee the breakdown
Technical Score (1D)
67
BULLISH
News Sentiment
32
BEARISH
On Nov 3, ProShares S&P 500 Dividend Aristocrats ETF (NOBL) liquidated its entire Kenvue (KVUE) position, selling $165.5 million of shares on Oct 30. That sale was the largest single move by the fund and contributed to a net outflow of $31.2 million for the ETF that day. NOBL’s exit followed a broader trend of ETFs reducing exposure to KVUE, with other funds also trimming holdings, indicating a shift in ETF sentiment toward the company. On Oct 30, ETFs collectively sold a net $530.3 million of KVUE shares, the second consecutive day of negative flows, with NOBL’s $165.5 million exit being the largest single transaction. The net outflow reflects ongoing caution among ETF managers toward KVUE amid market uncertainty. On Nov 2, UBS lowered its price target for KVUE from $19 to $20 while maintaining a neutral hold rating, citing that the company’s valuation remains modestly above current market levels. That same day, analysts noted KVUE’s 35.6% gain over the past year and its rebound from a 52‑week low near $14.06 to $19.31, but they remained cautious about future prospects.
LOW TARGET
$18 -8.0%
3 analysts
MEAN TARGET
$20 -0.3%
13 analysts
HIGH TARGET
$23 +17.6%
6 analysts
PRICE RANGE
$18.00 - $23.00
SB / B / H / S / SS
2/4/14/1/1
DAILYIQ EST.
$19.51 (-0.3%)
Sector
Consumer Defensive
Industry
Household & Personal Products
Exchange
NYQ
Country
United States
Website
Symbol
KVUE
Description
Kenvue Inc. is a global consumer health company with a diverse portfolio of well-known brands across three primary segments. The company's Self Care division focuses on over-the-counter medications and related products, including leading brands like Tylenol and Benadryl. Kenvue's Skin Health and Beauty segment features popular brands such as Neutrogena and Aveeno, while the Essential Health segment provides essential personal care products like Johnson's baby care and Band-Aid bandages. Operating internationally across multiple regions, Kenvue was established in 2022 and is headquartered in Summit, New Jersey, offering a broad range of consumer health solutions.
Bought (1Y)
0 shares
$0
Sold (1Y)
77,311 shares
$1.3M
Curado Gomes de Lemos LeonardoGroup President, Latin America
D4,150 shares2026-11-02
Curado Gomes de Lemos LeonardoGroup President, Latin America
Award/Grant4,150 shares2026-11-02
Curado Gomes de Lemos LeonardoGroup President, Latin America
D64,194 shares2026-11-02
Curado Gomes de Lemos LeonardoGroup President, Latin America
D12,818 shares2026-11-02
Curado Gomes de Lemos LeonardoGroup President, Latin America
D17,107 shares2026-11-02
63/ 100
Neutral / mixed
Overall: Neutral
✕Revenue declining year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
58.1%
Net Margin
9.7%
Revenue CAGR
0.2%
Current Ratio
0.96x
Debt / Equity
0.86x
Return on Equity
13.7%
Earnings Summary
In the last two quarters, Q1 2026 and Q2 2026, EPS rose to $0.32 and $0.31, slightly above estimates of $0.30627 and $0.31899, while revenue dipped to $3.909 billion and $3.955 billion from forecasts of $3.9189 billion and $4.0453 billion, indicating a modest revenue decline but maintaining earnings momentum. Historically, Kenvue has delivered mixed results: it beat EPS estimates in Q1 and Q2 2026 but missed in Q3 2026, and revenue has hovered near forecast levels with slight year‑over‑year declines in recent quarters. Recent news includes a $3.50 per share dividend announced on November 2, 2026, reinforcing the company’s commitment to shareholder returns, and a Q3 2026 report showing a 3.2% revenue increase and 8.0% net income rise, with a 10.9% profit margin expansion, signaling resilient profitability. The company’s focus on cost controls and product pipeline progress will be critical to maintaining its defensive positioning in the consumer health sector.

EPS

EstBeatMiss
$0.21$0.24$0.27$0.30$0.33Q3'25Q4'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$0.27 - -
Q3'26$0.30$0.29-3.5%
Q2'26$0.32$0.31-2.8%
Q1'26$0.31$0.32+4.5%
Q4'25$0.23$0.27+19.7%
Q3'25$0.26$0.28+5.7%

Revenue

EstBeatMiss
$3.7B$3.8B$3.9B$4.0B$4.1BQ3'25Q4'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$4.0B - -
Q3'26$3.9B$3.9B-1.4%
Q2'26$4.0B$4.0B-2.2%
Q1'26$3.9B$3.9B-0.3%
Q4'25$3.8B$3.8B+0.7%
Q3'25 - $3.8B -

Market Data

KVUE Stock Snapshot

BULLISH67/100
$19.60+$0.33 (1.7%)
Market cap
37.09B
P/E ratio
22.4
Day range
$0.00 – $0.00
News sentiment
32/100 · Bearish
Analyst target
$19.50 (-0.5%)
Consensus
Hold · 22 analysts
52-week range+23.0% off low · -2.6% from high
$15.94$20.13
Price $19.60 DailyIQ Est. $19.51

Kenvue Inc. ranks ahead of most of DailyIQ's universe on 12-month price momentum. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What KVUE's own history says about today's numbers

Realized volatility (21d)
21.3% 36th pct
Below its peak
-29.0%
vs 200-day average
+7.7%
Up days (1y)
51%

Kenvue Inc. is currently running 21.3% annualised volatility over the last 21 sessions. Measured against KVUE's own 3 years of daily returns rather than a market-wide average, that is the 36th percentile — on the quiet side for this stock, against a typical reading of 23.4%.

KVUE is trading -29.0% below its running peak. Across 3 full years on file, its median worst-drawdown-in-a-year was -18.4%, and the deepest was -42.1% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits +7.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 77th percentile — a somewhat wider gap than its own norm. Over the past year KVUE closed higher on 51% of sessions, and it is currently 2 sessions into a rising streak.

Overnight risk is measurable too: KVUE has opened more than 2% away from the prior close in 12 of 876 sessions (1.4% of the time), with the largest gaps running +4.0% and -3.1%.

Across the last 3 dated reports on file, KVUE moved an average of 0.8% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.1% and a largest of +1.8%.

All figures computed from 877 daily closes between 2023-05-04 and 2026-10-30, split-adjusted, recomputed daily. Percentiles are against KVUE's own 4-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of KVUE's sector?

Kenvue Inc. sits in the Consumer Staples sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#1 of 12
Sector state
Leading
Sector rotation score
100

Options Market

What is the options market pricing for KVUE?

CallsPuts

For Kenvue Inc.'s nearest expiry (2026-11-06, 0 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.20), with at-the-money implied volatility around 6.3%.

Put/call ratio (2026-11-06)
1.20
ATM implied volatility
6.3%
Total open interest
2,974

Analyst Consensus Estimates

What do analysts expect KVUE to earn?

Analysts expect Kenvue Inc. to earn $1.18 per share in the fiscal year ending Dec 2026 and $1.37 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026$0.28$0.26 to $0.324~$3.83B-
Dec 2026$0.26$0.25 to $0.289$3.89B8
Mar 2027$0.33$0.31 to $0.344$4.00B4
Jun 2027$0.31$0.29 to $0.332~$4.03B-
Sep 2027$0.29$0.27 to $0.322~$3.77B-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$1.18$1.11 to $1.2013$15.61B13
Dec 2027$1.24$1.13 to $1.3515$15.98B13
Dec 2028$1.30$1.28 to $1.322~$16.89B-
Dec 2029$1.37$1.36 to $1.372~$17.80B-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on KVUE?

UBS most recently reiterated its rating on Kenvue Inc. to Neutral on Nov 2, 2026 with a price target of $20 (from $19). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS: Neutral
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Nov 2, 2026UBSMaintainedNeutral$19 → $20
Aug 11, 2026UBSMaintainedNeutral$20 → $19
Jul 21, 2026BarclaysMaintainedEqual-Weight$18 → $19
Jul 16, 2026UBSMaintainedNeutral$18 → $20
Apr 15, 2026CitigroupMaintainedNeutral$20 → $19
Apr 14, 2026BarclaysMaintainedEqual-Weight$19 → $18
Apr 7, 2026UBSMaintainedNeutral$19 → $18
Mar 6, 2026BarclaysMaintainedEqual-Weight$18 → $19
Feb 18, 2026Canaccord GenuityMaintainedHold$17 → $18
Feb 18, 2026CitigroupMaintainedNeutral$18 → $20
Feb 18, 2026UBSMaintainedNeutral$17 → $19
Jan 30, 2026JefferiesDowngradeBuy → Hold$23 → $18

Earnings Release, Scored

What did Kenvue Inc.'s latest earnings release say?

Filed Oct 30, 2026 · SEC Form 8-K, Exhibit 99

Tone62.1/ 100-8.3 vs prior release
Hedging words1.55per 100 words+1.34 vs prior release
Tone, last 3 releasesScale 50–76

Most important lines

  1. 1

    Risks and uncertainties include, but are not limited to: the inability to execute on Kenvue’s business development strategy; inflation and other economic factors, such as interest rate and currency exchange rate fluctuations, as well as existing or proposed tariffs and other constraints on trade both in the U.S. and in foreign markets; the ability to successfully manage local, regional, or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow Kenvue to effect any dividend payments; Kenvue’s ability to maintain satisfactory credit ratings and access capital markets, which could adversely affect its liquidity, capital position, and borrowing costs; competition, including technological advances, new products, and intellectual property attained by competitors; challenges inherent in new product research and development; uncertainty of commercial success for new and existing products and digital capabilities; challenges to intellectual property protections, including counterfeiting; the ability of Kenvue to successfully execute strategic plans, including the 2026 Restructuring Initiative and any other restructuring or cost-saving initiatives; the impact of business combinations and divestitures, including any ongoing or future transactions; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations and other stakeholder requirements; changes in behavior and spending patterns of consumers; natural disasters, acts of war, or terrorism, catastrophes, or epidemics, pandemics, or other disease outbreaks; financial instability of international economies and legal systems and sovereign risk; the inability to realize the benefits of the separation from Kenvue’s former parent, Johnson & Johnson; the risk of disruption or unanticipated costs in connection with the separation; the Company’s inability to consummate the pending transaction with Kimberly-Clark due to, among other things, market, regulatory, and other factors; the potential for disruption to the Company’s business resulting from the pending transaction with Kimberly-Clark; and potential adverse effects on the Company’s stock price from the suspension or consummation of the pending transaction with Kimberly-Clark.

    New this quarterNegative tone
  2. 2

    Organic sales growth was driven by volume growth of 1.6% and favorable value realization of 1.3%.

  3. 3

    Organic sales decline was driven by a volume decrease of 1.7%, partially offset by favorable value realization of 1.2%.

    Negative tone

Peers & ETF holders

KVUE peers & ETF holders

News & sentiment

What is the news saying about KVUE?

KVUE rose 9.9% over the month to Oct 30. News tone held between 28 and 90 from Sep 30 to Oct 13, then dropped to 0 on Oct 14.

Daily close and news tone, Sep 30 to Oct 30
$18$20Sep 30: tone 30Oct 1: tone 44Oct 2: tone 37Oct 5: tone 60Oct 6: tone 29Oct 7Oct 8: tone 90Oct 9Oct 12Oct 13: tone 83Oct 14: tone 0Oct 15: tone 71Oct 16Oct 19: tone 50Oct 20: tone 34Oct 21: tone 58Oct 22: tone 75Oct 23Oct 26: tone 50Oct 27Oct 28Oct 29Oct 30: tone 74Sep 30News toneOct 30123
  1. Oct 1 -3.1%same day: Kenvue (KVUE) Stock Still Appears 41% Undervalued On Cash Flow
  2. Oct 15 +3.9%same day: What to Expect From Kenvue's Next Quarterly Earnings Report
  3. Oct 22 +3.9%
Latest stories naming Kenvue
ETFs Are Net Sellers of Kenvue (KVUE) on Oct. 30
Negative27Nov 3 · GuruFocus.com, Yahoo
Are Wall Street Analysts Bullish on Kenvue Stock?
Neutral50Nov 2 · Yahoo, Barchart
Kenvue Inc's Dividend Analysis
Leans positive57Nov 2 · GuruFocus.com

Technical analysis

How strong is KVUE's momentum right now?

On the daily chart KVUE ranks at the 67th percentile for momentum against 1,059 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling KVUE?

98 of the 208 tracked managers added to KVUE in their latest 13F and 104 trimmed. Together they own 79.7% of the company, worth $28.6B. Fidelity and BlackRock alone hold 16.3%.

98adding104trimming6unchanged
Largest holders by stake, latest 13FBar = share of KVUE
  1. $3.0B positionAdded 16.3% last quarter
  2. $2.9B positionAdded 3.8% last quarter
  3. $2.4B positionAdded 0.7% last quarter
  4. $2.3B positionAdded 1.7% last quarter
  5. $1.8B positionAdded 0.9% last quarter
  6. $990.2M positionAdded 1.5% last quarter
  7. $977.1M positionTrimmed 1.7% last quarter
  8. $882.1M positionAdded 5.2% last quarter
  9. $861.9M positionTrimmed 10.1% last quarter
  10. $705.9M positionAdded 16.2% last quarter
Full holdings history

Congressional trading

Is Congress trading KVUE?

8 members of Congress disclosed 21 KVUE trades between Sep 20, 2023 and Aug 5, 2026: 9 buys and 12 sells, about $192.5K in estimated value.

BuysSellsJan ’24JulJan ’25JulJan ’26Jul
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has KVUE done against its peers?

Over the six months to Oct 30, KVUE returned +11.6%. Of the 15 related stocks and ETFs, 5 did better, led by EL at +43.7%.

Change since Apr 30, through Oct 30
−40%−20%0%+20%+40%+60%Apr 30JunJulAugSepOctOct 30EL +43.7%KVUE +11.6%PEP −13.5%